TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial

Phase 2 Unknown 25 enrolled Peking Union Medical College Hospital

NaSingle-groupOpen-labelTreatment

Summary

To explore the effectiveness and safety of thalidomide, cyclophosphamide and prednisone (TCP regimen) in newly diagnosed Multicentric Castleman's disease (MCD) patients.

Timeline

Start: 2017-01-01
Primary completion: 2020-01-01
Completion: 2021-01-01

Publications

Zhang L, Zhao AL, Duan MH, Li ZY, Cao XX, Feng J, Zhou DB, Zhong DR, Fajgenbaum DC, Li J. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood. 2019 Apr 18;133(16):1720-1728. doi: 10.1182/blood-2018-11-884577. Epub 2019 Feb 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	300 mg/m2	Oral
Subject	Prednisone	Other / unclassified	1 mg/kg	Oral
Subject	Thalidomide	Other / unclassified	100 mg	Oral

TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial

Summary

Timeline

Publications

Drugs

Indications